Gold jewellers foresee higher footfall during the Indian festival
Vaccine maker Bharat Biotech on Monday announced that it has commenced Phase-3 trials of Covaxin, India's first indigenous vaccine for Covid-19.
The Phase-3 trials, which involve 26,000 volunteers across India, are being conducted in partnership with the Indian Council of Medical Research (ICMR).
This is India's first Phase-3 efficacy study for a Covid-19 vaccine, and the largest Phase-3 efficacy trial ever conducted in India, the Hyderabad-based company said.
Trial volunteers will receive two intramuscular injections approximately 28 days apart. Participants will be randomly assigned to receive Covaxin or a placebo. The trial is double blinded, such that the investigators, the participants and the company will not be aware of who is assigned to which group.
The trials are being conducted at 22 institutes in India including the All India Institute of Medical Sciences (AIIMS), the Guru Tegh Bahadur Hospital (both New Delhi), the Aligarh Muslim University, the Grant Government Medical College and Sir J.J. Group of Hospitals, Lokmanya Tilak Municipal General Hospital and Medical College (Sion Hospital) (all three Mumbai), the ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, the Directorate of Public Health and Preventive Medicine, Chennai and King George Hospital, Vizag.
Participating volunteers, who undergo vaccination in the Phase-3 trials, will be monitored to detect occurrence of Covid-19.
Covaxin has been evaluated in about 1,000 subjects in Phase-1 and Phase-2 clinical trials, with promising safety and immunogenicity data. Volunteers who wish to participate in this trial should be adults over 18 years of age.
Covaxin by Bharat Biotech is developed in collaboration with the ICMR - National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio containment facility.
Covaxin is a highly purified and inactivated vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied.
"The development and clinical evaluation of Covaxin marks a significant milestone for vaccinology in India, for a novel vaccine. It is important for Indian companies to innovate and develop indigenous vaccines, especially during a pandemic. Covaxin has garnered interest from several countries worldwide for supplies and introduction," said Suchitra Ella, Joint Managing Director of Bharat Biotech.
Gold jewellers foresee higher footfall during the Indian festival
Investors looked towards a US Federal Reserve Policy decision that could offer for more cues regarding its interest rate cuts policy
Around nine schools have received bomb threats so far, according to a Delhi Fire official; search operations underway
Demonstrators had vowed they would fight any eviction as they protested the soaring death toll from Israel's war with Hamas in the Gaza Strip
The vast archipelago nation, experiences frequent seismic and volcanic activity due to its position on the Pacific 'Ring of Fire'
The issue is seen as a potential vote winner for Biden as he faces Republican Donald Trump in a tough election rematch this November
Chance of light to moderate rain over Islands and some eastern and western areas
Indian actress Katrina Kaif talks about the power of being comfortable in your own skin as Kay Beauty, a brand she co-founded with Nykaa, makes its way to the UAE